INmune Bio Trims Q3 Loss to $4.7M, Sets Full UK Filing for February 2027
INMB is trading near its 52-week low of $1.09 (7.8% above the low).
Summary
INmune Bio cut its Q3 2026 net loss to about $4.7 million from $6.5 million a year earlier, with R&D down to $3.2 million and G&A to $1.8 million. Cash stood at $16.3 million on September 30; adding the $4.5 million October stock-and-warrant sale, management says funding lasts through Q3 2027 — a company with a going-concern history now has runway past its key regulatory dates. The regulatory plan shifted: instead of a rolling review, INmune now plans a complete Ebstrocel MAA to the UK MHRA in early February 2027, with an agency response expected three to six months later and potential UK approval mid-2027. The US BLA is targeted for mid-2027 and is being prioritized ahead of an EMA filing, and the Uniphar named-patient access deal gives a possible pre-approval revenue path in Europe, the Middle East and North Africa. The February 2027 MAA submission is the next hard date; a slip there pushes the mid-2027 approval expectation.
At the time of this announcement, INMB was trading at $1.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.6M. The 52-week trading range was $1.09 to $2.60. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.